Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.
Inflamm Bowel Dis. 2021 Jul 27;27(8):1184-1200. doi: 10.1093/ibd/izaa352.
Inflammatory bowel disease (IBD) has become a global disease encompassing a group of progressive disorders characterized by recurrent chronic inflammation of the gut with variable disease courses and complications. Despite recent advances in the knowledge of IBD pathophysiology, the elucidation of its etiopathology and progression is far from fully understood, requiring complex and multiple approaches. Therefore, limited clinical progress in diagnosis, assessment of disease activity, and optimal therapeutic regimens have been made over the past few decades. This review explores recent advances and challenges in tissue proteomics with an emphasis on biomarker discovery and better understanding of the molecular mechanisms underlying IBD pathogenesis. Future multi-omic studies are required for the comprehensive molecular characterization of disease biology in real time with a future impact on early detection, disease monitoring, and prediction of the clinical outcome.
炎症性肠病（IBD）已成为一种全球性疾病，它包含一组以肠道反复慢性炎症为特征的进行性疾病，其病程和并发症各不相同。尽管人们对 IBD 病理生理学的认识最近有所提高，但对其病因病理学和进展的阐明还远未完全了解，需要采用复杂的多种方法。因此，在过去几十年中，在诊断、疾病活动评估和最佳治疗方案方面的临床进展有限。本综述探讨了组织蛋白质组学的最新进展和挑战，重点是发现生物标志物和更好地了解 IBD 发病机制中的分子机制。未来需要进行多组学研究，以实时全面地对疾病生物学进行分子特征描述，从而对早期检测、疾病监测和临床结果预测产生影响。
